Literature DB >> 3512314

Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion.

M E Geffner, S A Kaplan, N Bersch, D W Golde, E M Landaw, R J Chang.   

Abstract

Six nonobese women with polycystic ovarian disease (PCOD) showed significant hyperinsulinemia, compared with controls after oral glucose (P less than 0.05). As an indicator of insulin sensitivity, in vitro proliferation of erythrocyte progenitor cells of PCOD subjects exposed to physiologic concentrations of insulin was significantly blunted (P less than 0.001). Monocyte insulin receptor binding was not impaired in the PCOD subjects. Three of the PCOD patients were treated with a long-acting gonadotropin-releasing hormone agonist for 6 months, which resulted in marked suppression of ovarian androgen secretion but no demonstrable changes in in vivo or in vitro indicators of insulin resistance. Thus insulin resistance in PCOD subjects appears to be unrelated to ovarian hyperandrogenism (or acanthosis or obesity). Although certain tissues are insulin-resistant in PCOD patients, the ovary may remain sensitive and overproduce androgens in response to high circulating insulin levels.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3512314

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  15 in total

Review 1.  The ovarian androgen-producing cells: a 2001 perspective.

Authors:  Denis A Magoffin
Journal:  Rev Endocr Metab Disord       Date:  2002-01       Impact factor: 6.514

2.  Testosterone, not 5α-dihydrotestosterone, stimulates LRH-1 leading to FSH-independent expression of Cyp19 and P450scc in granulosa cells.

Authors:  Yan-Guang Wu; Jill Bennett; Deepika Talla; Carlos Stocco
Journal:  Mol Endocrinol       Date:  2011-01-27

3.  Polycystic ovary syndrome: an enigma awaiting solution.

Authors:  M Schwartz; P R Gindoff; R Jewelewicz
Journal:  Bull N Y Acad Med       Date:  1987-03

4.  Hyperandrogenism, hyperinsulinism and polycystic ovarian disease.

Authors:  R Pasquali; S Venturoli
Journal:  J Endocrinol Invest       Date:  1986-12       Impact factor: 4.256

Review 5.  Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

Authors:  Carly E Kelley; Ann J Brown; Anna Mae Diehl; Tracy L Setji
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 6.  Insulin resistance in PCOS.

Authors:  Evanthia Diamanti-Kandarakis
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

7.  Insulin as a factor of increased androgen production in women with obesity and polycystic ovaries.

Authors:  R Pasquali; D Antenucci; F Casimirri; S Venturoli; R Paradisi; R Fabbri; N Melchionda; L Barbara
Journal:  J Endocrinol Invest       Date:  1987-12       Impact factor: 4.256

8.  Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility.

Authors:  Jennifer W Hill; Carol F Elias; Makoto Fukuda; Kevin W Williams; Eric D Berglund; William L Holland; You-Ree Cho; Jen-Chieh Chuang; Yong Xu; Michelle Choi; Danielle Lauzon; Charlotte E Lee; Roberto Coppari; James A Richardson; Jeffrey M Zigman; Streamson Chua; Philipp E Scherer; Bradford B Lowell; Jens C Brüning; Joel K Elmquist
Journal:  Cell Metab       Date:  2010-04-07       Impact factor: 27.287

9.  Massive Ovarian Growth in a Woman With Severe Insulin-Resistant Polycystic Ovary Syndrome Receiving GnRH Analogue.

Authors:  Prapti Singh; Ariela Agress; Vanessa Kasarah Madrigal; Clara Magyar; Nora Ostrzega; Gregorio Daniel Chazenbalk; Daniel Anthony Dumesic
Journal:  J Clin Endocrinol Metab       Date:  2019-07-01       Impact factor: 5.958

10.  Polycystic ovarian disease: endocrinological parameters with specific reference to growth hormone and somatomedin-C.

Authors:  W Urdl
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.